Overview

Therapy in Amyotrophic Lateral Sclerosis (TAME)

Status:
Completed

Trial end date:
2021-07-22

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine if memantine at 20 mg BID when used in conjunction with riluzole, can slow down the disease progression of patients with ALS including potentially improving their neuropsychiatric changes, as well as determine if serum biomarkers can be used both as a diagnostic and a prognostic marker in patients with ALS. Funding Source: FDA-OPD

Phase:

Phase 2

Details

Lead Sponsor:

University of Kansas Medical Center

Collaborator:

University of Missouri-Columbia

Treatments:

Memantine